Eli Lilly and Company Cash Flow Quality Index
Eli Lilly and Company cash flow quality index. Eli Lilly and Company (LILY34) has a Cash Flow Quality Index of 0.72x as of March 2026. Operating cash flow of R$5.33 Billion is below net income of R$7.40 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore LILY34 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Eli Lilly and Company (2014–2025)
Cash flow quality index of Eli Lilly and Company from 2014 to 2025. Historical Cash Flow Quality Index for Eli Lilly and Company across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Eli Lilly and Company balance sheet quality to measure how much of total assets are equity-financed.
Eli Lilly and Company Cash Flow Quality Index by Year (2014–2025)
Eli Lilly and Company cash flow quality index by year from 2014 to 2025. Year-by-year earnings quality comparison for Eli Lilly and Company. For the full cash flow conversion analysis, see Eli Lilly and Company (LILY34) cash conversion ratio.
| Year | Quality Index | Operating CF (BRL) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.81x | R$16.81 Billion | R$20.64 Billion | ▼ -2.2% |
| 2024 | 0.83x | R$8.82 Billion | R$10.59 Billion | ▼ -23.6% |
| 2023 | 1.09x | R$5.71 Billion | R$5.24 Billion | ▼ -3.9% |
| 2022 | 1.13x | R$7.08 Billion | R$6.24 Billion | ▼ -12.8% |
| 2021 | 1.30x | R$7.26 Billion | R$5.58 Billion | ▲ +24.0% |
| 2020 | 1.05x | R$6.50 Billion | R$6.19 Billion | ▲ +80.5% |
| 2019 | 0.58x | R$4.84 Billion | R$8.32 Billion | ▼ -66.0% |
| 2018 | 1.71x | R$5.52 Billion | R$3.23 Billion | ▼ -3.5% |
| 2016 | 1.77x | R$4.85 Billion | R$2.74 Billion | ▲ +44.0% |
| 2015 | 1.23x | R$2.96 Billion | R$2.41 Billion | ▼ -34.0% |
| 2014 | 1.87x | R$4.46 Billion | R$2.39 Billion | — |